Concepedia

Dose-proportionality Study Design

Dose-Proportionality Study Design is a research methodology that systematically varies drug dosage levels in a predetermined fashion to assess whether changes in exposure are directly proportional to changes in administered dose, thereby enabling pharmacokinetic evaluation of dose-proportionality across a defined therapeutic range.

39

Publications

2.8K

Citations

287

Authors

115

Institutions

Publications per year

2017–2026

8

Parents

Publications

39

Confidence Interval Criteria for Assessment of Dose Proportionality

Brian P. Smith · Pharmaceutical Research · 2000 · 352 citations

, , +13

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

Patricia Barditch‐Crovo, Steven G. Deeks, Ann Collier et al. · Antimicrobial Agents and Chemotherapy · 2001 · 333 citations · Full text

, , +16

Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party

Kevin Gough, Michael G. Hutchison, Oliver N. Keene et al. · Drug Information Journal · 1995 · 266 citations

, , +12

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study

Christie M. Ballantyne, Nicola Abate, Žhong Yuan et al. · American Heart Journal · 2005 · 240 citations

, , +14

The pharmacokinetics of meropenem in volunteers

Richard Bax, W Bastain, A. Featherstone et al. · Journal of Antimicrobial Chemotherapy · 1989 · 160 citations

, , +10

1–5 of 39

Authors

287

  1. MG
    Michael G. Hutchison

    University of Toronto, Canada

    2 publications · 426 citations

    2

    h-index

  2. SR
    Steven R. Cox

    W.E. Upjohn Institute for Employment Research, United States

    2 publications · 134 citations

    2

    h-index

  3. JF
    Joseph F. Boucher

    Pfizer (United States), United States

    2 publications · 134 citations

    2

    h-index

  4. SP
    S. P. LESMAN

    Pfizer (United States), United States

    2 publications · 134 citations

    2

    h-index

  5. AM
    A Marco

    PharmacoGenetics (China), China

    1 publications · 31 citations

    1

    h-index

1–5 of 287

Institutions

115

  1. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    3 h-index

    10 publications

    1.4K citations

  2. Pfizer (United States)

    New York, United States

    2 h-index

    15 publications

    977 citations

  3. Certara (United States)

    St Louis, United States

    2 h-index

    2 publications

    89 citations

  4. GlaxoSmithKline (United States)

    Philadelphia, United States

    2 h-index

    5 publications

    90 citations

  5. Gilead Sciences (United States)

    Foster City, United States

    2 h-index

    7 publications

    2K citations

  6. United States Military Academy

    West Point, United States

    2 h-index

    6 publications

    795 citations

  7. Celerion (United States)

    Lincoln, United States

    2 h-index

    4 publications

    223 citations

  8. Shanghai Clinical Research Center

    Shanghai, China

    1 h-index

    11 publications

    825 citations

1–8 of 115

Venues

  1. 3

    h-index

  2. The Journal of Clinical Pharmacology

    3 publications · 131 citations

    3

    h-index

  3. PubMed

    Repository · 2 publications · 42 citations

    2

    h-index

  4. Drug Information Journal

    DIA · 2 publications · 278 citations

    2

    h-index

  5. Clinical Therapeutics

    2 publications · 73 citations

    2

    h-index

1–5